Jun 01, 2020, CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial - Company Expects to Report Topline Data by the End of 2020 - SEATTLE , June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19.
We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.